반응형

eudamed 13

[Emergo, UL] Making the European Medical Device Nomenclature (EMDN) complete

What is the European Medical Device Nomenclature?Recently we updated you on Regulation (EU) 2024/1860 and how this amendment introduces a new approach on mandatory use of certain EUDAMED modules. Currently, 3 modules are live and those modules are expected to become mandatory in the upcoming year. One of the modules is the UDI/Device module. This module requires manufacturers to register their d..

뉴스 보고서 2025.02.07

[EU] MDCG 2024-15 - Guidance on the publication of the clinical investigation reports and their summaries in the absence of EUDAMED (November 2024)

1. Introduction Article 77(5) MDR requires that the sponsor submits to the Member States in which a clinical investigation was conducted a clinical investigation report within one year of the end of the clinical investigation or within three months of the early termination or temporary halt, irrespective of the outcome of the clinical investigation. Furthermore, the clinical investigation report..

유럽 MDR, IVDR 2024.12.18

[EU] MDCG 2024-14 - Guidance on the implementation of the Master UDI-DI solution for contact lenses (November 2024)

Introduction and scope The introduction of the Unique Device Identification (UDI) system referred to in Article 27 of Regulation (EU) 2017/745 on medical devices (MDR) aims to ensure an adequate level of identification and traceability with respect to medical devices. Basic UDI-DIs, UDI-DIs and UDIPIs shall be assigned (in compliance with the rules of the designated issuing entities) by manufac..

유럽 MDR, IVDR 2024.12.05

[EU, EUDAMED] Gradual roll out of EUDAMED - Q&As on practical aspects related to the implementation of Regulation (EU) 2024/1860 (November 2024)

Introduction – Objectives of the MDR/IVDR amendment The amendment of the MDR and of the IVDR through Regulation (EU) 2024/1860 addresses three topics:1. Regulation (EU) 2024/1860 aims to ensure a high level of patient safety and public health protection, including mitigation of risk of shortages of in vitro diagnostic medical devices (IVDs) needed for the smooth functioning of healthcare service..

유럽 MDR, IVDR 2024.12.02

[EU] MDCG 2023-3 rev.1 - Questions and Answers on vigilance terms and concepts as outlined in the Regulation (EU) 2017/745 under Regulation (EU) 2017/746

Introduction This document aims to clarify important terms and concepts that are outlined in Section 2 of Chapter VII of Regulation (EU) 2017/745 on medical devices (MDR) and Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). Establishing a common understanding of these terms and concepts is necessary for the effective and harmonised implementation of the vigilance requireme..

유럽 MDR, IVDR 2024.11.22

[EU, Conference] Information session on MDR/IVDR for international regulators – 4 July 2024

The EU Regulations on medical devices and in vitro diagnostic medical devices MDR, IVDR1. Extension of MDR transitional period    - 31 Dec 2027: class III, class IIb implantable    - 31 Dec 2028: Other class IIb, class IIa, class I m/s 2. Extension of IVDR transitional period    - 31 Dec 2027: devices covered by IVDD certificate and class D    - 31 Dec 2028: class C     - 31 Dec 2029: class B, c..

유럽 MDR, IVDR 2024.07.30

[CE, EU] MDCG 2022-9 rev.1 - Summary of safety and performance template - April 2024

Regulation (EU) 2017/746 on in vitro diagnostic medical devices (the IVDR) requires that the manufacturer shall draw up a summary of safety and performance (SSP) for class C and D devices, other than devices for performance studies. The SSP shall be validated by a notified body (NB) and made available to the public via the European database on medical devices (Eudamed). Text elements in italic i..

유럽 MDR, IVDR 2024.04.30
반응형